Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Garrett-Mayer

Showing results (231-240 of 275) with videos related to

Pageof 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit ScoreNathan I Cherny, Elisabeth G E de Vries, Urania Dafni, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|September 16, 2005
Pharmacologic and toxicologic evaluation of C. novyi-NT sporesLuis A Diaz, Ian Cheong, Catherine A Foss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinomaAndré Lopes Carvalho, Carmen Jeronimo, Michael M Kim, et al.
JCO Precision Oncology|April 30, 2026
Pertuzumab and Trastuzumab in Patients With <i>ERBB2/3</i>-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry StudyJohn K Chan, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Journal of the National Cancer Institute|December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in OncologyBrian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 3, 2011
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozoleTatiana M Prowell, Amanda L Blackford, Celia Byrne, et al.
Cancer Immunology Research|August 14, 2014
A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancerGang Chen, Richa Gupta, Silvia Petrik, et al.
JCO Precision Oncology|July 16, 2024
Palbociclib in Patients With Soft Tissue Sarcoma With <i>CDK4</i> Amplifications: Results From the Targeted Agent and Profiling Utilization Registry StudyScott Schuetze, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology|January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyEugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
JCO Oncology Practice|January 11, 2023
Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials: Evaluation of an ASCO-Association of Community Cancer Centers Site Self-AssessmentCarmen Guerra, Alice Pressman, Patricia Hurley, et al.
Pageof 28

Showing results (231-240 of 275) with videos related to

Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit ScoreNathan I Cherny, Elisabeth G E de Vries, Urania Dafni, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|September 16, 2005
Pharmacologic and toxicologic evaluation of C. novyi-NT sporesLuis A Diaz, Ian Cheong, Catherine A Foss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinomaAndré Lopes Carvalho, Carmen Jeronimo, Michael M Kim, et al.
JCO Precision Oncology|April 30, 2026
Pertuzumab and Trastuzumab in Patients With <i>ERBB2/3</i>-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry StudyJohn K Chan, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Journal of the National Cancer Institute|December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in OncologyBrian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 3, 2011
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozoleTatiana M Prowell, Amanda L Blackford, Celia Byrne, et al.
Cancer Immunology Research|August 14, 2014
A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancerGang Chen, Richa Gupta, Silvia Petrik, et al.
JCO Precision Oncology|July 16, 2024
Palbociclib in Patients With Soft Tissue Sarcoma With <i>CDK4</i> Amplifications: Results From the Targeted Agent and Profiling Utilization Registry StudyScott Schuetze, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology|January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyEugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
JCO Oncology Practice|January 11, 2023
Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials: Evaluation of an ASCO-Association of Community Cancer Centers Site Self-AssessmentCarmen Guerra, Alice Pressman, Patricia Hurley, et al.
Pageof 28